1. Home
  2. LGN vs EWTX Comparison

LGN vs EWTX Comparison

Compare LGN & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGN

Legence Corp.

N/A

Current Price

$48.45

Market Cap

2.4B

Sector

N/A

ML Signal

N/A

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$29.72

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGN
EWTX
Founded
1963
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.5B
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
LGN
EWTX
Price
$48.45
$29.72
Analyst Decision
Strong Buy
Buy
Analyst Count
15
8
Target Price
$43.43
$34.13
AVG Volume (30 Days)
1.1M
1.5M
Earning Date
11-14-2025
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,361,064,000.00
N/A
Revenue This Year
$17.08
N/A
Revenue Next Year
$32.52
N/A
P/E Ratio
N/A
N/A
Revenue Growth
46.19
N/A
52 Week Low
$26.96
$10.60
52 Week High
$50.20
$30.48

Technical Indicators

Market Signals
Indicator
LGN
EWTX
Relative Strength Index (RSI) N/A 65.13
Support Level N/A $25.92
Resistance Level N/A $28.29
Average True Range (ATR) 0.00 1.54
MACD 0.00 0.44
Stochastic Oscillator 0.00 95.18

Price Performance

Historical Comparison
LGN
EWTX

About LGN Legence Corp.

Legence Corp is a provider of engineering, installation and maintenance services for mission-critical systems in buildings. It focuses on high-growth sectors that have technically demanding buildings, including technology, life sciences, healthcare and education. The company specializes in designing, fabricating and installing complex HVAC, process piping and other mechanical, electrical and plumbing (MEP) systems for new facilities and upgrading HVAC, lighting and building controls in existing facilities to make them more energy efficient and sustainable.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: